Sysmex Europe and Cytek build a tiered clinical-flow workflow across more than a dozen European countries

Sysmex Europe and Cytek Biosciences announced a strategic collaboration on 9 September 2026 covering more than a dozen European countries. The companies describe a complementary workflow that links Sysmex's PS-10 automated sample preparation and XF-1600 routine clinical flow cytometer with Cytek's Northern Lights-CLC spectral flow cytometer.

CFCM explainer — a tiered laboratory architecture

PS-10 automated sample preparation → XF-1600 routine clinical flow → Northern Lights-CLC spectral flow for higher-dimensional applications.

Source/credit: CFCM conceptual workflow based on the joint Sysmex Europe/Cytek announcement, checked 3 October 2026. Alt text: workflow linking automated sample preparation, routine clinical flow cytometry and spectral flow cytometry.

The companies explicitly cite leukemia, lymphoma and measurable residual disease as areas where laboratories may use the combined offering. The announcement is commercially important because it frames conventional and spectral flow as complementary layers rather than direct substitutes.

Cytek's regulatory wording is important: the company states that its products are for research use only except Northern Lights-CLC and certain reagents, which are available for clinical use in China and the European Union. CFCM does not extend that status to other Cytek systems.

The partnership announcement contains manufacturer statements about workflow efficiency, standardisation and advanced clinical capabilities; these are not independent comparative validation data. The release does not provide the list of participating European countries, so CFCM records Europe-wide expansion as confirmed but Spain-specific inclusion as unverified. The combined architecture should not be interpreted as a validated reflex algorithm for leukemia, lymphoma or MRD without local assay validation and regulatory review.

For clinical cytometry, the strategic signal is the laboratory architecture. The market is moving away from simple cytometer-versus-cytometer comparisons toward integrated ecosystems that include sample preparation, routine acquisition, high-dimensional reflex capability, reagents, software and support. For European laboratories, spectral capacity may enter as a specialist layer on top of an established routine workflow rather than replacing it.